NCT02653755View on ClinicalTrials.gov

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

671

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Breast Cancer Radiation
Interventions
DEVICE

Prosigna

Transcriptional profile of 50 genes used for risk stratification.

Trial Locations (6)

10016

NYU Langone Health, New York

10065

Memorial Sloane Kettering Cancer Center, New York

21287

Johns Hopkins, Baltimore

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02903

Lifespan Cancer Institute, Providence

Sponsors
All Listed Sponsors
collaborator

NanoString Technologies, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02653755 - The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer | Biotech Hunter | Biotech Hunter